Mitiglinide (Calcium)
Mitiglinide (Calcium) structure
|
Common Name | Mitiglinide (Calcium) | ||
|---|---|---|---|---|
| CAS Number | 145525-41-3 | Molecular Weight | 334.44 | |
| Density | 1.175 | Boiling Point | 519.6ºC at 760 mmHg | |
| Molecular Formula | C19H24NO3Ca0.5 | Melting Point | 146-148ºC | |
| MSDS | USA | Flash Point | 268ºC | |
|
Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Diabetes Obes. Metab. 14(2) , 187-9, (2012) This study was performed to examine the efficacy and safety of mitiglinide in type 2 diabetes patients (T2DM). Enrolled patients had received treatment with diet and exercise in the previous 3 months with glycosylated haemoglobin (HbA1c) 7-10%, and were rando... |
|
|
Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Eur. J. Drug Metab. Pharmacokinet. 37(1) , 9-15, (2012) Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate onset as well as rapid disappearance of effect as compared wi... |
|
|
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Diabetes Obes. Metab. 14(2) , 130-8, (2012) Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic β-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vascular smooth muscle (SUR2B). Binding to SUR2A/SUR2B may inh... |
|
|
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Pharmacogenet. Genomics 22(3) , 206-14, (2012) The common ATP-sensitive potassium (KATP) channel variants E23K and S1369A, found in the KCNJ11 and ABCC8 genes, respectively, form a haplotype that is associated with an increased risk for type 2 diabetes. Our previous studies showed that KATP channel inhibi... |
|
|
Pleiotropic effects of mitiglinide in type 2 diabetes mellitus.
J. Int. Med. Res. 37(6) , 1904-12, (2009) This study investigated the effects of mitiglinide in 16 patients with type 2 diabetes mellitus treated with 30 mg/day mitiglinide, divided into three doses given just before each meal, for approximately 12 months. A 450 kcal meal tolerance test was performed... |
|
|
Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies.
Biomed. Chromatogr. 22(8) , 873-8, (2008) A sensitive and specific method was developed and validated for the determination of mitiglinide in human plasma using liquid chromatographic separation with electrospray ionization tandem mass spectrometric detection. Acidified plasma samples were extracted ... |
|
|
Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy.
Endocr. J. 56(6) , 739-46, (2009) This study was performed to examine the efficacy and safety of the rapid- and short-acting insulinotropic SUR ligand mitiglinide given as add-on therapy for 52 weeks in type 2 diabetic patients whose blood glucose was insufficiently controlled by pioglitazone... |
|
|
Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial.
Endocr. J. 56(5) , 657-64, (2009) A 16-week, multicenter, randomized, double blind, parallel-group study was performed to examine whether additional administration of mitiglinide improves glycemic control in Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone m... |
|
|
The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies.
J. Clin. Pharm. Ther. 37(1) , 95-9, (2012) Mitiglinide (MGN) is a new insulinotropic agent of the glinide class with rapid onset. The effects of food intake on the pharmacokinetic (PK) profile of mitiglinide tablets after single oral administration have not yet been reported in healthy adults. We aime... |
|
|
Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
Endocr. J. 57(7) , 579-86, (2010) Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor ligand and features rapid hypoglycemic action. To date, no prospective study has evaluated the use of mitiglinide in diabetic patients receiving hemodialysis (HD). In this study we ... |